Physician

Sreecharan Reddy Mavuram, M.D

According to 2025 Medicare claims, Sreecharan Mavuram, M.D (NPI: 1396078291) practices medical oncology in the San Antonio-New Braunfels, TX market, with the plurality of this provider's patient population coming from Bexar, TX. This provider's primary affiliated billing organization is ONCOLOGY SAN ANTONIO (NPI: 1790180370; TIN: 472050793) and primary practice location at 78215-1907. Mavuram is affiliated with the Ochsner Accountable Care Network, LLC (ACO ID: A1535) and CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Mavuram's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 514 traditional Medicare patients, billed 391,970 HCPCS/CPT codes, and received $3,997,401 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,913 prescription claims across 365 beneficiaries totaling $2,667,905 in drug costs, led by Jakafi (Ruxolitinib Phosphate). DME data shows 15 claims. Open Payments data shows 182 records totaling $4,388. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $160,517 to $3,997,401. Similarly, Part D prescription costs have moved sharply higher in recent years, from $27,055 to $2,667,905. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $6,605 to $1,354.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	622	1,738	$160,517
2016	693	1,715	$156,666
2017	596	1,745	$146,059
2018	414	1,130	$97,709
2019	171	951	$77,937
2020	73	381	$31,218
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	514	391,970	$3,997,401

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	142	535	$27,055
2016	111	274	$14,258
2017	107	253	$8,109
2018	93	253	$20,183
2019	58	283	$110,267
2020	77	215	$160,688
2021	131	418	$223,422
2022	111	314	$21,421
2023	99	274	$345,160
2024	365	1,913	$2,667,905

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	69	$4,780
2016	N/R	32	$1,535
2017	N/R	30	$1,039
2018	N/R	52	$1,663
2019	N/R	42	$1,932
2020	N/R	N/R	N/R
2021	N/R	22	$1,145
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	15	$551

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	234	571	$131
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	448	1,610	$89
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	108	557	$46
96367	Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less	103	1,961	$21
96372	Injection of drug or substance under skin or into muscle	105	751	$10

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	33	990	$527,257
Lenalidomide	Lenalidomide	23	644	$365,133
Imbruvica	Ibrutinib	17	484	$302,277
Kisqali	Ribociclib Succinate	16	399	$270,694
Ibrance	Palbociclib	12	322	$187,573

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	15	$551

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	182	$4,388	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Sreecharan Reddy Mavuram, M.D?

Tedicare shows public-source Medicare data for Sreecharan Reddy Mavuram, M.D (NPI 1396078291), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Sreecharan Reddy Mavuram, M.D have ACO affiliation data?

Sreecharan Reddy Mavuram, M.D is shown with ACO affiliation data for Ochsner Accountable Care Network, LLC (MSSP, ACO ID A1535) and CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Sreecharan Reddy Mavuram, M.D?

Sreecharan Reddy Mavuram, M.D is linked to ONCOLOGY SAN ANTONIO (billing NPI 1790180370) in the available physician profile data.

Does Sreecharan Reddy Mavuram, M.D have Open Payments data?

Sreecharan Reddy Mavuram, M.D has 182 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.